United Therapeutics Announces Agreement To Acquire Priority Review Voucher
Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™
News provided by
Share this article
Share this article
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2020 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The PRV entitles the holder to designate an NDA for priority review and provides for an expedited eight-month review, instead of the standard twelve-month review period. Following the close of the transaction, United Therapeutics intends to apply the PRV to its NDA for Tyvaso DPI, expected in the first half of 2021.
News No Comments
Tyra Robinson will graduate with a Bachelor of Science degree in health education and promotion and a minor in health and exercise science. After graduation, she plans to go to graduate school to become a licensed physical therapist.
Tell us a little bit about yourself.
I am from McGehee, Arkansas, and graduated from McGehee High School in 2015. I played basketball in junior high and high school, and I was also a majorette.
My mom and the majority of my family still live in McGehee, and my dad lives in Little Rock. Moving to Little Rock was a huge change for me. My hometown only has only one stoplight, and it seems like Little Rock has one million.
Inside the new mRNA vaccines for COVID-19
How the Pfizer and Moderna vaccines work to prime the human immune system to fight SARS-CoV-2 By Jim Fessenden December 18, 2020
Health care workers across the nation this week are the first Americans to receive the new mRNA vaccine by Pfizer/BioNTech to protect against COVID-19, and the Moderna vaccine appears soon to follow, with emergency approval by the Food and Drug Administration possible any day. The new mRNA vaccines are the first of their kind and researchers at UMass Medical School are among the leading RNA biologists in the world. The Medical School is home to the
The following story originally appeared on the W&M Alumni Magazine website. - Ed.
When people ask what Melissa J. Moore ’84 does for a living, she often says, “I work for you.”
That was literally true when the biochemist and molecular biologist received federal funding for her academic research. And in an important way, it still is. As the chief scientific officer of platform research at Massachusetts-based Moderna Inc., Moore is a key part of the biotech company’s effort to produce 200 million COVID-19 vaccines for the U.S. government to distribute to Americans across the country.
“It’s a way to draw people in,” Moore says of her response to the question. “It’s so important for scientists to be out there communicating with the public. We are in it for the public good.”